BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 24419755)

  • 1. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
    Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
    Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
    Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
    Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
    Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
    Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reliable risk score for stage IV esophagogastric cancer.
    Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
    Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
    Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
    Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy.
    Badgwell B; Ajani J; Blum M; Ho L; Fournier K; Chiang YJ; Matamoros A; Das P; Mansfield P
    Ann Surg Oncol; 2016 Jan; 23(1):156-62. PubMed ID: 26059652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation.
    Piessen G; Messager M; Leteurtre E; Jean-Pierre T; Mariette C
    Ann Surg; 2009 Dec; 250(6):878-87. PubMed ID: 19855261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
    Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
    Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
    Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
    Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signet ring cells in esophageal and gastroesophageal junction carcinomas have a more aggressive biological behavior.
    Nafteux PR; Lerut TE; Villeneuve PJ; Dhaenens JM; De Hertogh G; Moons J; Coosemans WJ; Van Veer HG; De Leyn PR
    Ann Surg; 2014 Dec; 260(6):1023-9. PubMed ID: 24836142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
    Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
    Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
    Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
    Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.